BlueRock Therapeutics announces publication in Nature of 18-month data from Phase 1 clinical trial for bemdaneprocel, an investigational cell therapy for Parkinson's disease
BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidiary of Bayer AG, announced the publication of the 18-month data from its Phase 1 exPDite clinical trial for bemdaneprocel in the journal Nature. "The concept of "rebuilding" brain networks that have been lost to disease is compelling," said Claire Henchcliffe, MD, chair of the UC Irvine School of Medicine's Department of Neurology at the University of California, Irvine and one of the study's Principal Investigators,
BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidiary of Bayer AG, announced the publication of the 18-month data from its Phase 1 exPDite clinical trial for bemdaneprocel in the journal Nature.
"The concept of "rebuilding" brain networks that have been lost to disease is compelling," said Claire Henchcliffe, MD, chair of the UC Irvine School of Medicine's Department of Neurology at the University of California, Irvine and one of the study's Principal Investigators,
